FDA Approved: OCREVUS — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Ocrevus (ocrelizumab) from Genentech, Inc. This action approves changes to the BLA submission for this product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Ocrevus (ocrelizumab)

Snippet

SUPPL AP for OCREVUS (OCRELIZUMAB)